Previous studies have reported that FOSL2 can indirectly promote angiogenesis in tumor tissues, even when classical VEGF signaling is inhibited by anti-VEGF antibodies or axitinib.36 These findings suggest that FOSL2 may be adaptively upregulated in response to antiangiogenic therapies such as lenvatinib and sorafenib. This evidence concerns the gene VEGFA and neoplasm.